Browse by author
Lookup NU author(s): Professor John IsaacsORCiD, Emerita Professor Helen Foster
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
Eligibility for anti-tumour necrosis factor (TNF) therapy in most European countries is restricted to severe, active rheumatoid arthritis (RA). The DAS28 score is a marker of disease severity and incorporates one of two inflammatory markers, erythrocyte sedimentation rate (ESR) or C-reactive protein. We aimed to determine the relation between genetic variants known to affect ESR and levels of ESR in patients with active RA. DNA samples were genotyped for four single-nucleotide polymorphisms (SNPs) rs7527798 (CR1L), rs6691117 (CR1), rs10903129 (TMEM57) and rs1043879 (C1orf63). The association between SNPs and baseline ESR, baseline DAS28-ESR, and change in DAS28-ESR was evaluated. Baseline ESR was significantly associated with CR1 rs6691117 genotype (P=0.01). No correlation was identified between baseline DAS28-ESR or change in DAS28-ESR. In conclusion, genetic variation in the gene encoding CR1 may alter ESR levels but not DAS28-ESR, indicating no adjustment for CR1 genotype is required in the assessment of patients with severe active RA.
Author(s): Bluett J, Ibrahim I, Plant D, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Barton A, BRAGGSS
Publication type: Article
Publication status: Published
Journal: Pharmacogenomics Journal
Year: 2014
Volume: 14
Issue: 2
Pages: 171-175
Print publication date: 16/07/2013
Acceptance date: 29/05/2013
Date deposited: 03/07/2014
ISSN (print): 1470-269X
ISSN (electronic): 1473-1150
Publisher: Nature Publishing Group
URL: http://dx.doi.org/10.1038/tpj.2013.26
DOI: 10.1038/tpj.2013.26
Altmetrics provided by Altmetric
